Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
PR Newswire
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 7, 2026
View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisks-cagrisema-2-4-mg--2-4-mg-demonstrated-significant-reduction-in-hba1c-and-weight-across-multiple-studies-in-the-reimagine-program-presented-at-ada-2026--302793443.htmlSOURCE NOVO NORDISK INC.
The articles, information, and content displayed on this webpage may
